GGrantIndex
← Leaderboards

Jeffrey H Kordower

Rush University Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$13,504,856
Attributed
$23,596,721
Total exposure
16
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,596,721 · 16

By mechanism

R01$14,823,670 · 7
R24$5,183,524 · 1
R21$2,179,224 · 4
P01$974,205 · 3
R33$436,098 · 1

Top collaborators

Most similar at Rush University Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Dopamine”

Research focus

DopamineBrainParkinson DiseasePreventMotorNonhuman PrimateDosePrimatesPathologySafetyCorpus Striatum StructureGeneticPre-ClinicalRattusPharmaceutical PreparationsGene TherapyLevodopaBaseMediatingGenesPhenotypeMonkeysDisease ModelIn Vivo

Grant awards (48)

Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$643,792
R01 · FY2025 · NS
Tau based Monkey model of Alzheimer's Disease; Structure and Function$1,295,737
R24 · FY2024 · AG
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$952,368
R01 · FY2024 · NS
Tau based Monkey model of Alzheimer's Disease; Structure and Function$1,295,737
R24 · FY2023 · AG
Tau based Monkey model of Alzheimer's Disease; Structure and Function$1,296,257
R24 · FY2022 · AG
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$468,320
R01 · FY2022 · NS
Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease$436,098
R33 · FY2022 · NS
Tau based Monkey model of Alzheimer's Disease; Structure and Function$1,295,793
R24 · FY2021 · AG
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$568,415
R01 · FY2021 · NS
Human iPSC-based personalized cell therapy of PD$591,114
R01 · FY2020 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$590,058
R01 · FY2020 · NS
Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease$449,748
R21 · FY2020 · NS
Human iPSC-based personalized cell therapy of PD$647,507
R01 · FY2019 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$561,645
R01 · FY2019 · NS
Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease$471,170
R21 · FY2019 · NS
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$432,538
R01 · FY2019 · NS
Does alpha synuclein strain or GCase enzyme activity drive clinical aggression in GBA-PD?$235,500
R21 · FY2019 · NS · contact PI
Human iPSC-based personalized cell therapy of PD$644,754
R01 · FY2018 · NS
Genetic Silencing of Striatal CaV1.3 Calcium Channels as a Potent Antidyskinetic Therapy for PD$598,419
R01 · FY2018 · NS
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$410,256
R01 · FY2018 · NS
Does alpha synuclein strain or GCase enzyme activity drive clinical aggression in GBA-PD?$196,250
R21 · FY2018 · NS · contact PI
Human iPSC-based personalized cell therapy of PD$647,555
R01 · FY2017 · NS
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$557,329
R01 · FY2017 · NS
Human iPSC-based personalized cell therapy of PD$660,673
R01 · FY2016 · NS
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$576,131
R01 · FY2016 · NS
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease$489,414
R01 · FY2015 · NS
Human Cell and Gene Therapy in Parkinsonian monkeys$184,556
R21 · FY2013 · NS · contact PI
Human Cell and Gene Therapy in Parkinsonian monkeys$229,500
R21 · FY2012 · NS · contact PI
Human Neural Stem Cells for HD: Technical and Empirical Advances$225,000
R21 · FY2012 · NS · contact PI
Human Neural Stem Cells for HD: Technical and Empirical Advances$187,500
R21 · FY2011 · NS · contact PI
TH and GTPCHI gene therapy for Parkinson's disease$513,992
R01 · FY2010 · NS · contact PI
TH and GTPCHI gene therapy for Parkinson's disease$618,821
R01 · FY2009 · NS · contact PI
TH and GTPCHI gene therapy for Parkinson's disease$465,614
R01 · FY2008 · NS · contact PI
TH and GTPCHI gene therapy for Parkinson's disease$523,997
R01 · FY2007 · NS · contact PI
ESTROGEN AND MONKEY HIPPOCAMPAL NEUROGENESIS$326,921
P01 · FY2007 · AG · contact PI
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$445,511
R01 · FY2006 · NS · contact PI
ESTROGEN AND MONKEY HIPPOCAMPAL NEUROGENESIS$248,705
P01 · FY2006 · AG · contact PI
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$50,000
R01 · FY2006 · NS · contact PI
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$443,717
R01 · FY2005 · NS
ESTROGEN AND MONKEY HIPPOCAMPAL NEUROGENESIS$241,462
P01 · FY2005 · AG
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$393,605
R01 · FY2004 · NS
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$420,971
R01 · FY2003 · NS
DYSKINESIAS IN LENTI-GDNF TREATED PARKINSONIAN MONKEYS$437,077
R01 · FY2002 · NS
MESOFRONTAL DOPAMINERGIC SYSTEMS IN MCI AND AD$0
P01 · FY2002 · AG
MESOFRONTAL DOPAMINERGIC SYSTEMS IN MCI AND AD$0
P01 · FY2001 · AG
CHOLINERGIC GRAFTS &COGRAFTS FOR COGNITIVE DISFUNCTION$262,176
R01 · FY2000 · NS
NGF GRAFTS AND HUNTINGTONS DISEASE$207,901
R01 · FY2000 · NS
NERVE GROWTH FACTOR TROPISM IN THE PROGRESSION OF ALZHEIMER'S DISEASE$157,117
P01 · FY2000 · AG